Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul-Aug;36(4):1911-1915.
doi: 10.21873/invivo.12911.

The Role of PPAR-gamma C161T Polymorphism in Colorectal Cancer Susceptibility

Ozlem Kurnaz-Gomleksiz  1 , Bahar Canbay Torun  2 , Turgay Isbir  3 , Turker Bulut  4 , Necmettin Sokucu  4 , Hulya Yilmaz-Aydogan  5 , Emel Canbay  6
Affiliations

The Role of PPAR-gamma C161T Polymorphism in Colorectal Cancer Susceptibility

Ozlem Kurnaz-Gomleksiz et al. In Vivo. 2022 Jul-Aug.

Abstract

Background/aim: This study aimed to determine the role of the peroxisome proliferator-activated receptor-gamma (PPARg) C161T genotype and allele frequencies in predisposition to colorectal cancer (CRC).

Patients and methods: PPARg C161T (His447His; rs3856806) gene polymorphisms were determined by polymerase chain reaction-restriction fragment length polymorphism analysis in patients with CRC (n=101) and controls (n=238).

Results: The T161 allele (CT+TT genotypes) of PPARg C161T polymorphism was associated with CRC development (p<0.001; OR=3.239, 95%CI=1.997-5.252). Subgroup analysis showed that the T161 allele was associated with a 3.056-fold increased risk for colon cancer (CC) (p<0.001; 95%CI=1.709-5.464) and 3.529-fold increased risk for rectal cancer (RC) (p<0.001; 95%C=1.784-6.981). Frequencies of the T161 allele were also higher in total CRC and CC patients with poorly differentiated tumors (p<0.001, c2=30,601, OR=3.109; 95%CI=1.970-4.906 and p<0.001, Fisher exact test, respectively).

Conclusion: PPARg T161 allele carriers have increased risk for developing CRC.

Keywords: PPARg C161T polymorphism; Turkish population; colorectal cancer.

PubMed Disclaimer

Conflict of interest statement

The Authors declare no conflicts of interest in relation to this study.

References

    1. Weitz J, Koch M, Debus J, Höhler T, Galle PR, Büchler MW. Colorectal cancer. Lancet. 2005;365(9454):153–165. doi: 10.1016/S0140-6736(05)17706-X. - DOI - PubMed
    1. Butterly LF, Goodrich M, Onega T, Greene MA, Srivastava A, Burt R, Dietrich A. Improving the quality of colorectal cancer screening: assessment of familial risk. Dig Dis Sci. 2010;55(3):754–760. doi: 10.1007/s10620-009-1058-z. - DOI - PMC - PubMed
    1. Potter JD. Colorectal cancer: molecules and populations. J Natl Cancer Inst. 1999;91(11):916–932. doi: 10.1093/jnci/91.11.916. - DOI - PubMed
    1. Krishnan A, Nair SA, Pillai MR. Biology of PPAR gamma in cancer: a critical review on existing lacunae. Curr Mol Med. 2007;7(6):532–540. doi: 10.2174/156652407781695765. - DOI - PubMed
    1. Ding H, Chen Y, Qiu H, Liu C, Wang Y, Kang M, Tang W. PPARG c.1347C>T polymorphism is associated with cancer susceptibility: from a case-control study to a meta-analysis. Oncotarget. 2017;8(60):102277–102290. doi: 10.18632/oncotarget.20925. - DOI - PMC - PubMed